azathioprine has been researched along with Bone Diseases, Metabolic in 4 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "At the distal radius, osteopenia was found in all the groups." | 2.69 | Bone loss in long-term renal transplantation: histopathology and densitometry analysis. ( Adams, JE; Crowley, V; Cueto-Manzano, AM; France, MW; Freemont, AJ; Gokal, R; Hutchison, AJ; Konel, S; Mawer, B, 1999) |
| "There is a high prevalence of low bone mineral density (BMD) among patients with inflammatory bowel disease (IBD) although there is a lack of clinical data on the impact of IBD specific medications and recommended vitamin D (VD) and calcium (Ca) supplements on it." | 1.40 | Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients. ( Cierny, D; Hlavaty, T; Huorka, M; Killinger, Z; Koller, T; Krajcovicova, A; Letkovsky, J; Miznerova, E; Nevidanska, M; Payer, J; Toth, J; Zelinkova, Z, 2014) |
| "Osteoporosis, osteopenia, and osteonecrosis are common in renal transplant recipients." | 1.36 | Bone disease in renal transplantation and pleotropic effects of vitamin D therapy. ( Balal, M; Binokay, F; Demir, E; Erken, U; Kurt, C; Paydas, S; Sertdemir, Y; Sikgenc, MM, 2010) |
| "Azathioprine treatment alone did not alter ionized calcium, 1,25(OH)2VitD, or PTH levels." | 1.29 | Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. ( Armstrong, EC; Bryer, HP; Buchinsky, FJ; Epstein, S; Isserow, JA; Mann, GN; Romero, DF; Rucinski, B, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krajcovicova, A | 1 |
| Hlavaty, T | 1 |
| Killinger, Z | 1 |
| Miznerova, E | 1 |
| Toth, J | 1 |
| Letkovsky, J | 1 |
| Nevidanska, M | 1 |
| Cierny, D | 1 |
| Koller, T | 1 |
| Zelinkova, Z | 1 |
| Huorka, M | 1 |
| Payer, J | 1 |
| Sikgenc, MM | 1 |
| Paydas, S | 1 |
| Balal, M | 1 |
| Demir, E | 1 |
| Kurt, C | 1 |
| Sertdemir, Y | 1 |
| Binokay, F | 1 |
| Erken, U | 1 |
| Bryer, HP | 1 |
| Isserow, JA | 1 |
| Armstrong, EC | 1 |
| Mann, GN | 1 |
| Rucinski, B | 1 |
| Buchinsky, FJ | 1 |
| Romero, DF | 1 |
| Epstein, S | 1 |
| Cueto-Manzano, AM | 1 |
| Konel, S | 1 |
| Hutchison, AJ | 1 |
| Crowley, V | 1 |
| France, MW | 1 |
| Freemont, AJ | 1 |
| Adams, JE | 1 |
| Mawer, B | 1 |
| Gokal, R | 1 |
1 trial available for azathioprine and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Bone loss in long-term renal transplantation: histopathology and densitometry analysis.
Topics: Absorptiometry, Photon; Adult; Age Factors; Anti-Inflammatory Agents; Azathioprine; Bone Density; Bo | 1999 |
3 other studies available for azathioprine and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Combination therapy with an immunomodulator and anti-TNFα agent improves bone mineral density in IBD patients.
Topics: Absorptiometry, Photon; Adalimumab; Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; A | 2014 |
Bone disease in renal transplantation and pleotropic effects of vitamin D therapy.
Topics: Azathioprine; Bone Density; Bone Diseases; Bone Diseases, Metabolic; Creatinine; Female; Humans; Kid | 2010 |
Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat.
Topics: Animals; Azathioprine; Body Weight; Bone Diseases, Metabolic; Calcitriol; Calcium; Cyclosporine; Dis | 1995 |